Farther Finance Advisors’s Fate Therapeutics FATE Stock Holding History

Farther Finance Advisors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$275	Sell	116 -1,562	-93%	-$4.04K	﹤0.01%	5840
2026 Q2	$4.47K	Buy	1,678 +1,058	+171%	+$1.96K	﹤0.01%	4858
2026 Q1	$769	Buy	620 +520	+520%	+$633	﹤0.01%	5177
2025 Q4	$98	Buy	+100	New	+$120	﹤0.01%	5301
2024 Q3	–	Sell	-100	Closed	-$326	–	4042
2024 Q2	$326	Buy	+100	New	+$438	﹤0.01%	3376
2023 Q1	–	Sell	-35	Closed	-$353	–	2376
2022 Q4	$353	Buy	+35	New	+$657	﹤0.01%	1909

Other funds holding FATE

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's FATE Position: Q3 2026 in Review

Farther Finance Advisors reduced its Fate Therapeutics (FATE) stake by 93% in Q3 2026, selling an estimated $4.04K and leaving 116 shares worth $275. The position accounts for ﹤0.01% of the portfolio, ranked #5840.

Farther Finance Advisors first reported a position in FATE in Q4 2022 and has held it in 6 quarters since. The position peaked at $4.47K in Q2 2026. 2 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

Farther Finance Advisors held 116 shares of Fate Therapeutics worth $275 as of Q3 2026.
Farther Finance Advisors sold 1,562 Fate Therapeutics shares in Q3 2026, an estimated $4.04K.
Fate Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5840 holding.
Farther Finance Advisors first reported a position in Fate Therapeutics in Q4 2022 and has held it in 6 quarters since.
Farther Finance Advisors's Fate Therapeutics position peaked at $4.47K in Q2 2026.
2 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.